UK companies Avacta and Glythera have sealed a licensing deal to develop drug conjugates using their combined technologies. More: Avacta, Glythera link to develop drug conjugates Source: News
read moreThe Scottish Medicines Consortium has rejected NHS funding for four new therapies, including Bristol-Myers Squibb and Roche’s respective cancer medicines Opdivo and Gazyvaro. More: SMC bars four medicines from NHS Source: News
read moreUS regulators have approved a supplemental New Drug Application for Boehringer Ingelheim’s lung cancer drug Gilotrif for first-line treatment of patients with metastatic non-small cell lung cancer whose tumours have non-resistant epidermal growth factor receptor. More: US expands scope of
read moreSouth Korea’s Samsung is tamping down investor excitement about a fourth biologics manufacturing site after its Samsung BioLogics CEO suggested it could be built sooner than later. More: Samsung backtracks on executive’s remarks about timing for 4th biologics plant Source:
read moreAs one of our coverage team said as the J.P. Morgan Healthcare Conference was winding down Thursday, this first-of-the-year meeting sets the tone for months to come. And it’s certainly a great place to suss out the general biopharma mood
read moreTeva Pharmaceuticals, which has already paid half a billion dollars in U.S. penalties for having bribed foreign doctors, has now settled with authorities in Israel, but for a fraction of that amount. More: Israeli authorities cut Teva some slack as foreign
read more© 1994 - 2026 B.M. Pharmaceuticals